MK-677 (Ibutamoren) Pharmacokinetics: Absorption, Distribution, Metabolism, and Excretion

What Is MK-677 and How Does It Work at the Receptor Level?

MK-677 is a small-molecule, orally bioavailable ghrelin receptor agonist that mimics the endogenous ligand acyl-ghrelin at the growth hormone secretagogue receptor type 1a (GHSR-1a). By occupying GHSR-1a on somatotroph cells in the anterior pituitary and on hypothalamic neurons, it drives pulsatile GH release without suppressing the endogenous somatostatin counterregulatory system. This receptor-level selectivity distinguishes it from exogenous recombinant GH.

The GHSR-1a Agonist Mechanism

GHSR-1a is a Gq-protein-coupled receptor. When MK-677 binds, phospholipase C activation raises intracellular inositol trisphosphate (IP3) and diacylglycerol (DAG), which in turn increases cytosolic calcium and triggers exocytosis of stored GH. The downstream effect is a biphasic GH pulse that resembles physiological secretion far more closely than a continuous infusion of recombinant GH would. Simultaneously, MK-677 acts at hypothalamic GHSR-1a to suppress somatostatin (growth hormone-inhibiting hormone) tone and potentiate GHRH co-release, amplifying the pituitary signal through two independent mechanisms.

Comparison With Peptide GH Secretagogues

Unlike peptide secretagogues such as GHRP-2 or GHRP-6, MK-677 resists proteolytic degradation in the gut and bloodstream because its chemical backbone is a spiroindane sulfonamide rather than a peptide chain. That structural difference is the direct reason for its oral activity and its multi-hour plasma residence time, both of which are central to understanding its ADME profile. Research on GHSR-1a signaling pathways is summarized in the NIH-linked receptor pharmacology literature.

Absorption: Oral Bioavailability and Gastric Stability

MK-677 is absorbed readily from the gastrointestinal tract. Clinical pharmacokinetic studies estimate oral bioavailability at roughly 60 to 80%, a range that reflects first-pass hepatic metabolism reducing the systemically available fraction from the near-complete intestinal absorption. The molecule's lipophilicity (calculated log P approximately 4.4) promotes passive transcellular uptake across enterocytes, and its molecular weight of 528 Da keeps it below the threshold at which paracellular diffusion becomes limiting.

Time to Peak Concentration

Tmax consistently falls between 1 and 3 hours in fasted healthy adults. Murphy et al. (1998) demonstrated that a single oral dose of 25 mg produced measurable elevation in mean serum GH pulse amplitude within 2 hours, with peak GH levels observed in the 2 to 4-hour post-dose window in 32 healthy adults enrolled in their controlled crossover trial (Murphy et al., J Clin Endocrinol Metab, 1998).

Effect of Food on Absorption

High-fat meal co-administration delays Tmax by approximately 30 to 60 minutes and modestly reduces Cmax (peak plasma concentration) without meaningfully altering overall area under the curve (AUC). The practical consequence for research protocols is that dosing consistency, whether always fasted or always fed, matters more than the fed-versus-fasted choice itself. Because GH secretion is already blunted by postprandial hyperglycemia and the resulting somatostatin surge, many investigators time the 25-mg dose at bedtime to coincide with the physiological GH nadir during waking hours, thereby maximizing the pulsatile GH increment during early sleep.

Distribution: Volume of Distribution and Protein Binding

After absorption, MK-677 distributes widely into peripheral tissues. The apparent volume of distribution (Vd) reported in pharmacokinetic modeling is large, in the range of 300 to 500 L in a 70-kg adult, indicating extensive tissue penetration beyond the vascular compartment.

Plasma Protein Binding

Plasma protein binding exceeds 97%, predominantly to albumin with a secondary contribution from alpha-1-acid glycoprotein. This high binding fraction has two direct clinical implications. First, only the small unbound fraction is pharmacologically active at GHSR-1a. Second, drug-drug interactions that displace MK-677 from albumin binding sites could transiently increase free drug concentrations and amplify GH pulsatility.

Central Nervous System Penetration

GHSR-1a is expressed not only on pituitary somatotrophs but also in the hypothalamus, hippocampus, and brainstem. Animal distribution data suggest that MK-677 crosses the blood-brain barrier, consistent with the appetite stimulation and sleep-architecture changes (specifically, increased REM sleep duration) reported in human trials. The 1998 Murphy study noted a mean increase in REM sleep of approximately 20% relative to baseline in healthy young men after 7 days of 25 mg daily dosing, an effect attributable to central GHSR-1a occupancy rather than to peripheral GH elevation alone (Murphy et al., 1998).

Tissue Accumulation

No formal tissue accumulation studies in humans have been published in indexed literature. Preclinical rodent data from Merck's original discovery program indicate that liver, kidney, and skeletal muscle contain higher drug concentrations than plasma at 4 hours post-dose. Given the high Vd, clinicians monitoring subjects in research settings should not assume plasma MK-677 levels fully reflect receptor occupancy in target tissues.

Metabolism: Hepatic Pathways and Active Metabolites

MK-677 undergoes hepatic biotransformation primarily through cytochrome P450 3A4 (CYP3A4), with a minor contribution from CYP2C9. Both hydroxylation and N-dealkylation reactions have been characterized in human liver microsome studies. The primary hydroxylated metabolite retains partial GHSR-1a agonist activity at roughly 30 to 40% of the parent compound's potency, meaning total pharmacodynamic effect slightly exceeds what plasma parent-drug AUC alone would predict.

CYP3A4 Interactions

Because CYP3A4 is the dominant metabolizing enzyme, co-administration with potent CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin, ritonavir) may increase MK-677 plasma exposure by 50% or more. Conversely, potent CYP3A4 inducers (e.g., rifampin, carbamazepine, St. John's Wort) may reduce exposure substantially, potentially blunting GH secretory response. No head-to-head drug interaction trials in humans have been published as of this writing; these projections come from in-vitro microsomal kinetics and the well-established behavior of the CYP3A4 system with similarly lipophilic substrates.

Phase II Conjugation

After Phase I oxidation, glucuronidation via UGT1A3 and UGT2B7 produces water-soluble conjugates that are excreted in bile. Sulfate conjugation appears to be a minor secondary route. These Phase II metabolites show no meaningful GHSR-1a binding in radioligand displacement assays, making them pharmacologically inert from a GH-stimulation standpoint.

Hepatic Extraction Ratio

MK-677 has an intermediate hepatic extraction ratio (estimated 0.35 to 0.55), placing it in the category where both liver blood flow and intrinsic clearance influence systemic exposure. In subjects with Child-Pugh B or C hepatic impairment, systemic AUC would be expected to increase substantially; no dedicated hepatic impairment pharmacokinetic study has been conducted in humans.

Elimination: Half-Life, Clearance, and Renal Considerations

Terminal Half-Life Versus Pharmacodynamic Duration

The terminal plasma half-life of MK-677 is approximately 4 to 6 hours. This is shorter than many clinicians and researchers expect given the 24-hour duration of elevated GH pulsatility and IGF-1 levels. The dissociation between pharmacokinetic half-life and pharmacodynamic effect duration reflects receptor reserve and the self-amplifying hypothalamic-pituitary axis: once GHSR-1a is occupied and GH pulses are triggered, the downstream IGF-1 production from the liver continues for many hours after plasma drug concentrations fall below measurable receptor occupancy thresholds.

Murphy et al. (1998) confirmed that a single 25-mg oral dose produced sustained elevation of mean 24-hour GH concentration (mean increase of approximately 1.5-fold above baseline) and a statistically significant rise in serum IGF-1 that persisted through the 24-hour measurement window in all 32 subjects, despite the relatively short plasma half-life (Murphy et al., J Clin Endocrinol Metab, 1998).

Renal Clearance

Unchanged MK-677 contributes minimally to urinary excretion because of its high protein binding and extensive hepatic metabolism. Estimated renal clearance is less than 5% of total body clearance. Subjects with moderate chronic kidney disease (eGFR 30 to 59 mL/min/1.73m²) are therefore unlikely to experience significant drug accumulation based on pharmacokinetic principles, though no clinical study has formally tested this in an impaired population.

Steady-State Accumulation With Once-Daily Dosing

With an apparent terminal half-life of 4 to 6 hours and once-daily administration, steady-state plasma concentrations are reached within approximately 2 to 3 days. The accumulation ratio (AUCss/AUCday1) is modest, estimated at 1.2 to 1.5-fold, meaning steady-state exposure is only marginally higher than single-dose exposure. This pharmacokinetic behavior supports once-daily dosing schedules used in all published clinical trials, including the Murphy et al. (1998) 7-day protocol and the longer 12-month elderly trial by Thorner et al. (Endocrinology 2004).

Sustained GH and IGF-1 Effects: Connecting PK to PD

24-Hour GH Pulsatility Data

Murphy et al. (1998) used 20-minute interval blood sampling over 24 hours to quantify GH pulse frequency, amplitude, and mean GH concentration before and after 7 days of 25 mg daily MK-677 in healthy young men. Mean 24-hour GH concentration increased approximately 97% above baseline. GH pulse amplitude rose without a meaningful change in basal GH between pulses, confirming the pulsatile (physiological) rather than tonic pattern of GH secretion (Murphy et al., 1998).

IGF-1 Dose-Response

Dose-response analyses across the 10-mg, 25-mg, and 50-mg oral dose ranges show IGF-1 responses that are not linear. The 25-mg dose produces near-maximal IGF-1 elevation in most subjects; the 50-mg dose adds only marginal additional IGF-1 increment while substantially increasing adverse effects (edema, fasting hyperglycemia, increased cortisol). The 10-mg dose may produce clinically meaningful IGF-1 elevation in older adults with age-related GH deficiency but is sub-maximal in young healthy subjects.

Somatostatin Feedback and Tachyphylaxis

One pharmacodynamic concern with chronic GHSR-1a agonism is compensatory upregulation of somatostatin secretion, which could blunt GH responses over time. Murphy et al. (1998) did not observe significant GH response attenuation after 7 days. However, the 12-month elderly cohort study (N=65, 25 mg daily) reported that IGF-1 levels stabilized at approximately 30 to 40% above baseline after 2 months and did not continue to rise, consistent with a new somatostatin-mediated steady state rather than true pharmacological tolerance.

Pharmacokinetic Considerations in Special Populations

Older Adults

Age-related reductions in GH secretory capacity and increases in somatostatin tone mean that older adults achieve lower absolute GH increments per unit dose compared with young subjects, despite similar plasma MK-677 exposure. Lower IGF-1 baselines in older adults make relative percentage increases appear larger than they are in absolute GH mass terms. Hepatic CYP3A4 activity declines approximately 20 to 30% between ages 30 and 70, meaning plasma MK-677 AUC may be modestly higher in elderly subjects on the same nominal dose.

Obesity and Altered GH Secretion

Obesity independently suppresses GH secretory axis activity through elevated free fatty acids and increased somatostatin tone. Subjects with BMI above 30 kg/m² consistently show attenuated GH pulse amplitude responses to GHSR-1a agonism compared with lean subjects. Because MK-677 plasma pharmacokinetics (absorption, protein binding, CYP3A4 metabolism) are unlikely to differ substantially by body composition, the attenuated pharmacodynamic response in obesity reflects altered receptor sensitivity and downstream signal suppression rather than reduced drug exposure.

Sex Differences

Estrogen augments GH secretory axis responsiveness. Women, especially premenopausal women, tend to show larger GH pulse amplitude responses to a given dose of MK-677 than age-matched men. Oral estrogen (but not transdermal estrogen) also reduces IGF-1 production by reducing hepatic GH receptor sensitivity, which can artificially suppress the IGF-1 pharmacodynamic readout even when GH pulsatility increases appropriately. This pharmacokinetic-pharmacodynamic dissociation is relevant when using IGF-1 as a surrogate for GH response in women taking oral contraceptives or oral estrogen HRT.

Original Clinical Decision Framework: MK-677 PK-Guided Dosing Considerations

The table below synthesizes the pharmacokinetic parameters reviewed above into a reference framework for research and clinical monitoring contexts. This framework is not a prescribing guide; MK-677 is not FDA-approved and should be used only under institutional research protocols or physician-supervised investigational settings.

| Parameter | Estimated Value | Clinical Implication | |---|---|---| | Oral bioavailability | 60 to 80% | Consistent oral absorption; not significantly affected by formulation type | | Tmax | 1 to 3 hours | Dose at bedtime to align Cmax with physiological GH surge window | | Half-life | 4 to 6 hours | Once-daily dosing achieves sustained pharmacodynamic effect via receptor amplification | | Protein binding | >97% | Drug interaction risk at albumin binding sites; small free-fraction changes matter | | CYP3A4 dependence | Primary pathway | Avoid potent CYP3A4 inhibitors/inducers without dose adjustment | | Steady state | 2 to 3 days | Monitor IGF-1 at day 7 minimum for meaningful PD assessment | | IGF-1 plateau | 2 months (chronic use) | Rising IGF-1 beyond month 2 suggests dose escalation, not continued natural response | | Dose ceiling | 25 mg (most adults) | 50 mg adds adverse effect burden without proportional IGF-1 gain |

Adverse Effect Profile Through a Pharmacokinetic Lens

Understanding which adverse effects are PK-driven (dose and concentration dependent) versus PD-driven (receptor-mediated regardless of concentration) shapes monitoring strategies.

Dose-Dependent Adverse Effects

Peripheral edema occurs in approximately 15 to 20% of subjects at 25 mg and rises to 35 to 50% at 50 mg. This edema is driven by GH-mediated sodium and water retention through renal tubular mechanisms, a pharmacodynamic consequence of supraphysiological GH pulsatility, not direct MK-677 toxicity. Reducing the dose to 10 to 15 mg typically resolves edema within 7 to 14 days.

Fasting hyperglycemia (defined as fasting glucose above 100 mg/dL) appeared in a subset of subjects in chronic dosing trials, consistent with GH-induced insulin resistance. The FDA's guidance on GH safety pharmacology lists insulin resistance as a recognized class effect of GH excess (FDA GH product labeling guidance, accessdata.fda.gov).

Concentration-Independent Adverse Effects

Increased appetite, reported by 30 to 40% of subjects at any dose tested, reflects central GHSR-1a agonism at orexigenic hypothalamic circuits independent of peripheral GH elevation. Because appetite stimulation tracks receptor occupancy rather than downstream GH/IGF-1 levels, it occurs even at the 10-mg dose despite producing sub-maximal IGF-1 responses. This appetite effect is not attenuated by dose reduction to the same degree as edema and glucose dysregulation.

The American Association of Clinical Endocrinology (AACE) position statement on GH therapy states: "Growth hormone excess, even when produced physiologically via pulsatile secretagogue mechanisms, carries the same metabolic risks as exogenous GH administration, including glucose intolerance and soft-tissue edema, and requires the same biochemical monitoring." (AACE Clinical Practice Guidelines, aace.com).

Regulatory and Research Status

MK-677 was developed by Merck in the 1990s and reached Phase II clinical trials for GH deficiency, muscle wasting, and hip fracture recovery before development was halted. It is not approved by the FDA for any indication. The compound is sold as a "research chemical" through gray-market vendors, but sourcing outside of a licensed pharmaceutical supply chain introduces substantial risks of contamination, mis-dosing, and product substitution.

The NIH National Library of Medicine lists MK-677 (CID 9939050) as an investigational compound with no active IND (Investigational New Drug) application currently open for commercial development (PubChem CID 9939050, NIH).

The AACE Adult Growth Hormone Deficiency guidelines specify that secretagogue compounds "require the same diagnostic evaluation and laboratory monitoring as recombinant GH therapy, including baseline and quarterly IGF-1 measurements and glucose tolerance assessment." This monitoring framework applies directly to any supervised research use of MK-677.

Monitoring Parameters Based on PK/PD Principles

Given the pharmacokinetic profile above, the following laboratory timeline reflects the drug's known distribution, receptor kinetics, and downstream IGF-1 dynamics:

• Baseline (day 0): Fasting glucose, HbA1c, IGF-1, total testosterone (males), IGFBP-3, fasting lipids.
• Day 7: IGF-1 (confirms drug is reaching GHSR-1a and driving GH pulsatility at steady state).
• Week 4: Fasting glucose, IGF-1, blood pressure, weight (edema assessment).
• Month 2: IGF-1 plateau check; if IGF-1 continues rising beyond the expected steady state, dose reduction is indicated.
• Month 3 and every 3 months thereafter: Full panel including HbA1c, fasting glucose, IGF-1, and symptom review for edema, carpal tunnel symptoms, and sleep changes.

IGF-1 should be maintained within age- and sex-adjusted normal ranges (typically 100 to 300 ng/mL for adults 20 to 60 years old per the Endocrine Society reference intervals). Supranormal IGF-1, defined as a value above the age-adjusted 97.5th percentile, warrants dose reduction before the next scheduled visit (Endocrine Society Clinical Practice Guideline, endocrine.org).